SG10201909413SA - Method of treating medulloblastoma with an ezh2 inhibitor - Google Patents
Method of treating medulloblastoma with an ezh2 inhibitorInfo
- Publication number
- SG10201909413SA SG10201909413SA SG10201909413SA SG10201909413SA SG 10201909413S A SG10201909413S A SG 10201909413SA SG 10201909413S A SG10201909413S A SG 10201909413SA SG 10201909413S A SG10201909413S A SG 10201909413SA
- Authority
- SG
- Singapore
- Prior art keywords
- ezh2 inhibitor
- medulloblastoma
- treating
- ezh2
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000000172 Medulloblastoma Diseases 0.000 title abstract 3
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 239000003623 enhancer Substances 0.000 abstract 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 abstract 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 abstract 1
- 229950004774 tazemetostat Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238074P | 2015-10-06 | 2015-10-06 | |
| US201662299312P | 2016-02-24 | 2016-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201909413SA true SG10201909413SA (en) | 2019-11-28 |
Family
ID=58488487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909413S SG10201909413SA (en) | 2015-10-06 | 2016-10-05 | Method of treating medulloblastoma with an ezh2 inhibitor |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190083504A1 (enExample) |
| EP (2) | EP4309738A3 (enExample) |
| JP (1) | JP7045985B2 (enExample) |
| KR (1) | KR20180058829A (enExample) |
| CN (1) | CN108699046A (enExample) |
| AU (3) | AU2016333982A1 (enExample) |
| CA (1) | CA3000983A1 (enExample) |
| EA (1) | EA201890878A1 (enExample) |
| IL (2) | IL258510A (enExample) |
| MX (1) | MX394355B (enExample) |
| SG (1) | SG10201909413SA (enExample) |
| WO (1) | WO2017062495A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| WO2019018635A1 (en) | 2017-07-19 | 2019-01-24 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT |
| JP7399079B2 (ja) | 2017-09-05 | 2023-12-15 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| EP3976044A4 (en) * | 2019-06-03 | 2024-08-07 | Icahn School of Medicine at Mount Sinai | Compounds and methods for inhibiting cancers via rest inhibition |
| CN111905102A (zh) * | 2020-09-04 | 2020-11-10 | 福建医科大学附属第一医院 | Ezh2抑制剂在治疗胶质瘤中的应用 |
| KR102821233B1 (ko) | 2022-02-10 | 2025-06-17 | 서울대학교병원 | Hsp70을 표적으로 하는 수모세포종 치료 및 전이 억제 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4236945A (en) * | 1978-11-27 | 1980-12-02 | Allegheny Ludlum Steel Corporation | Phosphorus-iron powder and method of producing soft magnetic material therefrom |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US8846935B2 (en) * | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| MX2012012966A (es) | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| JO3363B1 (ar) * | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR20190105669A (ko) * | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| PL2953941T3 (pl) | 2013-02-11 | 2017-11-30 | Constellation Pharmaceuticals, Inc. | Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania |
| MX373187B (es) * | 2013-12-06 | 2020-04-13 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| WO2017079757A1 (en) * | 2015-11-06 | 2017-05-11 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
-
2016
- 2016-10-05 WO PCT/US2016/055554 patent/WO2017062495A2/en not_active Ceased
- 2016-10-05 EP EP23199696.8A patent/EP4309738A3/en not_active Withdrawn
- 2016-10-05 SG SG10201909413S patent/SG10201909413SA/en unknown
- 2016-10-05 KR KR1020187012552A patent/KR20180058829A/ko not_active Ceased
- 2016-10-05 AU AU2016333982A patent/AU2016333982A1/en not_active Abandoned
- 2016-10-05 CN CN201680070432.7A patent/CN108699046A/zh active Pending
- 2016-10-05 EA EA201890878A patent/EA201890878A1/ru unknown
- 2016-10-05 CA CA3000983A patent/CA3000983A1/en not_active Abandoned
- 2016-10-05 EP EP16854241.3A patent/EP3371175A4/en not_active Withdrawn
- 2016-10-05 JP JP2018517399A patent/JP7045985B2/ja not_active Expired - Fee Related
- 2016-10-05 US US15/766,474 patent/US20190083504A1/en not_active Abandoned
- 2016-10-05 MX MX2018004132A patent/MX394355B/es unknown
-
2018
- 2018-04-05 IL IL258510A patent/IL258510A/en unknown
-
2020
- 2020-01-31 US US16/778,274 patent/US20200268765A1/en not_active Abandoned
-
2021
- 2021-03-08 IL IL281318A patent/IL281318A/en unknown
- 2021-06-25 AU AU2021204331A patent/AU2021204331A1/en not_active Abandoned
-
2023
- 2023-10-09 AU AU2023246384A patent/AU2023246384A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018529742A (ja) | 2018-10-11 |
| CA3000983A1 (en) | 2017-04-13 |
| EP3371175A2 (en) | 2018-09-12 |
| IL258510A (en) | 2018-05-31 |
| KR20180058829A (ko) | 2018-06-01 |
| IL281318A (en) | 2021-04-29 |
| CN108699046A (zh) | 2018-10-23 |
| AU2016333982A1 (en) | 2018-04-26 |
| EA201890878A1 (ru) | 2018-08-31 |
| EP4309738A3 (en) | 2024-07-17 |
| US20190083504A1 (en) | 2019-03-21 |
| JP7045985B2 (ja) | 2022-04-01 |
| WO2017062495A2 (en) | 2017-04-13 |
| WO2017062495A3 (en) | 2017-06-08 |
| AU2021204331A1 (en) | 2021-07-22 |
| MX394355B (es) | 2025-03-24 |
| MX2018004132A (es) | 2018-09-26 |
| AU2023246384A1 (en) | 2023-11-02 |
| EP4309738A2 (en) | 2024-01-24 |
| EP3371175A4 (en) | 2019-09-25 |
| US20200268765A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4309738A3 (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
| MX2017003933A (es) | Metodos de tratamiento de la enfermedad hepatica. | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| MX2016013375A (es) | Tratamiento de la hgna y ehna. | |
| MX2017007095A (es) | Metodos y composiciones de activacion de la ligasa parkin. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| MX2021007003A (es) | Método para tratar el cáncer. | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| MX2017006022A (es) | Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular. | |
| HK1256042A1 (zh) | 用於治疗糖尿病周围神经病变的hdac抑制剂 | |
| MX2021007899A (es) | Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6. | |
| PH12017501980A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
| MX2015008310A (es) | Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. | |
| MX2017004819A (es) | Metodos de tratamiento de transtornos urológicos usando sarm. | |
| MX2022005888A (es) | Metodos para tratar afecciones oculares. | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MX2017009313A (es) | Formulaciones intravenosas de baclofeno y metodos de tratamiento. | |
| NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| MX2020005454A (es) | Tratamiento de cancer mejorado. |